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ABSTRACT 
Lung cancer is the leading cause of death from cancer in the world. First, 
we hypothesized that microRNA expression is altered in the bronchial epithelium 
of patients with lung cancer and that incorporating microRNA expression into an 
existing mRNA biomarker may improve its performance.  
Using bronchial brushings collected from current and former smokers, we 
profiled microRNA expression via small RNA sequencing for 347 patients with 
available mRNA data. We found that four microRNAs were under-expressed in 
cancer patients compared to controls (p<0.002, FDR<0.2). We explored the role 
of these microRNAs and their gene targets in cancer. In addition, we found that 
adding a microRNA feature to an existing 23-gene biomarker significantly 
improves its performance (AUC) in a test set (p<0.05). 
Next, we generalized the biomarker discovery process, and developed a 
visualization tool for biomarker selection. We built upon an existing biomarker 
discovery pipeline and created a web-based interface to visualize the 
performance of multiple predictors. The “visualization” component is the key to 
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sorting through a thousand potential biomarkers, and developing clinically useful 
molecular predictors. 
Finally, we explored the molecular events leading to the development of 
COPD and ILD, two heterogeneous diseases with high mortality. We 
hypothesized that integrative genetic and expression networks can help identify 
drivers and elucidate mechanisms of genetic susceptibility.  
We utilized 262 lung tissue specimens profiled with microRNA 
sequencing, microarray gene expression and SNP chip genotyping. Next, we 
built condition specific integrative networks using a causality inference test for 
predicting SNP-microRNA-mRNA associations, where the microRNA is a 
predicted mediator of the SNP’s effect on gene expression. We identified the 
microRNAs predicted to affect the most genes within each network. Members of 
miR-34/449 family, known to promote airway differentiation by repressing the 
Notch pathway, were among the top ranked microRNAs in COPD and ILD 
networks, but not in the non-disease network. In addition, the miR-34/449 gene 
module was enriched among genes that increase in expression over time when 
airway basal cells are differentiated at an air-liquid interface and among genes 
that increase in expression with the airway wall thickening in patients with 
emphysema. 
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CHAPTER ONE 
Introduction 
 
1.1 Lung cancer 
Lung cancer remains the leading cause of cancer death in the world due, 
in large part, to our inability to detect the disease at its earliest and curable stage. 
The high mortality rate (80–85% within 5 years) (Siegel, Naishadham, and Jemal 
2013) results, in part, from a lack of effective diagnostic options to detect this 
disease at an early stage. Symptoms of early stage lung cancer are mild and 
non-specific, such as a cough, shortness in breathing and tiredness, which can 
be associated with other benign conditions. Therefore, most patients are 
diagnosed at late stages associated with poor prognosis (Novaes et al. 2008). 
About 224,000 new diagnoses and 160,000 deaths were recorded in 2014, 90% 
of which are due to smoking (“Cancer of the Lung and Bronchus - SEER Stat 
Fact Sheets” 2016). Lung cancer is classified in two main histological subtypes, 
such as small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). 
SCLC develops in the upper airways and it is the most aggressive type of lung 
cancer that metastasizes quickly to other parts of the body (“Lung Cancer - Small 
Cell: MedlinePlus Medical Encyclopedia” 2016). However, SCLC represents only 
15% of all lung cancer cases. Most lung cancers are NSCLC, and they are 
further classified into adenocarcinoma, squamous cell carcinoma and large cell 
carcinoma (Ginsberg, Grewal, and Heelan 2007). 
  2
Like most of other cancers, lung cancer is a heterogeneous disease with 
complex molecular profiles (Collisson et al. 2014; Hammerman et al. 2012). 
Recently, targeted therapies have worked successfully in patients with activated 
somatic oncogenes. For example, patients with EGFR mutations are showing 
response to EGFR targeted compounds, such as Erlotinib and Gefitinib 
(Greenhalgh et al. 2015; Wang, Schmid-Bindert, and Zhou 2012; Kim et al. 
2011). Also, BRAF and ERBB2 genes are currently being investigated as 
potential therapeutic targets (Collisson et al. 2014; Stephens et al. 2004). 
Mutational profiles of lung cancer may also depend on the exposure to different 
carcinogenic compounds. For example, EGFR mutations are more common in 
never-smokers (Govindan et al. 2012). The complex molecular mechanisms of 
lung cancer are still poorly understood and there is a tremendous need to 
develop better diagnostic and therapeutic strategies. 
 
1.2 Using the airway molecular field of injury to predict lung cancer  
Chronic inflammation has been previously associated with tumorigenesis 
in different tissue types, such as lung (Zhai et al. 2008; Fujimoto et al. 2012), 
colon (Terzić et al. 2010) and skin (Maru et al. 2014). The airway is constantly 
affected by the exposure to different carcinogens and toxins, leading to chronic 
inflammation and ultimately to lung disease. Our laboratory has previously shown 
that the alterations that may occur in the distal part of the lung tissue are also 
reflected in the normal airway epithelial cells. The ability to identify gene 
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expression changes associated with smoking and cancer status in the normal 
appearing airway supports the idea of an airway molecular field of injury 
spanning the respiratory tract (Spira et al. 2007; Brody 2012; Beane et al. 2011; 
Steiling, Lenburg, and Spira 2009). Recently, a gene expression biomarker for 
lung cancer detection has been developed, a test that is now used clinically 
(Whitney et al. 2015; Silvestri et al. 2015).  
In this work, we extend the field of injury concept to microRNAs. We 
characterize the microRNA expression changes associated with the presence of 
lung cancer in bronchial epithelium from the mainstem bronchus and show that 
these alterations can be used to improve lung cancer detection. 
 
1.3 Biomarker discovery 
High throughput technologies have been used to profile genes in multiple 
different dimensions, such as gene and protein expression, genetic variation, 
copy number and epigenetics. An important use of gene expression data is the 
classification of cancer patients with respect to genes that are either up or down 
regulated in a specific tissue. Gene expression classifiers have been developed 
for lung cancer detection (Silvestri et al. 2015; Whitney et al. 2015), breast 
cancer tumors (van ’t Veer et al. 2002; Popovici et al. 2010), or prognosis of colo-
rectal cancer (Bertucci et al. 2004).  In 2006, Micro Array Quality Control (MAQC) 
project (MAQC Consortium et al. 2006), a community-wide effort involving 137 
participants from 51 organizations, established the best practices of developing 
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molecular classifiers.  Multiple statistical and machine learning algorithms have 
been tested and compared. Using bootstrapping, they have shown that a 
genomic predictor’s accuracy is determined largely by an interplay between 
sample size and data heterogeneity, and that multiple feature selection and 
classification algorithms may produce statistically equally good predictors 
(Popovici et al. 2010; MAQC Consortium et al. 2006). Based on the methods 
described by MAQC project, our lab has developed a new tool for biomarker 
discovery. This thesis presents a methodology of visually selecting the best 
combination of methods that can leverage a clinically useful biomarker in a given 
dataset. 
 
1.4 Chronic obstructive pulmonary disease and interstitial lung disease 
Chronic obstructive pulmonary disease (COPD) is a progressive lung 
disease and the fourth leading cause of death worldwide (Osei et al. 2015), with 
an incidence of 2.8 cases per 1,000 population per year (Raherison and Girodet 
2009). COPD is a very heterogeneous disease, with the two most common types 
of COPD being chronic bronchitis and emphysema. COPD consists of narrowing 
of the small airways and breakdown of lung tissue and it is mainly caused by 
tobacco smoking. Although biological processes, such as chronic inflammation, 
apoptosis, and oxidative stress, have been found to play a role in COPD 
pathogenesis, knowledge remains limited about the molecular mechanisms of 
this disease (Steiling et al. 2013).  
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Interstitial lung disease (ILD) is another heterogeneous group of chronic 
respiratory disorders, with the most common ILD being idiopathic pulmonary 
fibrosis (IPF). ILD has a lower incidence (6.8-8.8 per 100,000 population per year 
(Nalysnyk et al. 2012)) than COPD, but it is a disease with high mortality 
characterized by an interstitial fibrotic process (Gribbin et al. 2006; Raghu et al. 
2006; Raghu et al. 2011). ILD is characterized by a progressive scarring of lung 
tissue, that may cause lung stiffness (Nathan et al. 2015). The most common 
symptom of ILD is shortness of breath. These diseases may be caused by an 
infection with bacteria (Mycoplasma pneumonia), viruses or fungi, or the cause 
may be unknown, as it is the case of IPF. There are no effective therapies for IPF 
(Bjoraker et al. 1998; Carrington et al. 1978; Stack, Choo-Kang, and Heard 
1972), therefore understanding the molecular drivers underlying this condition 
may improve therapeutic strategies and patients outcome. 
This thesis addresses three chronic lung diseases, such as ILD, COPD 
and lung cancer, by leveraging expression profiles and complex molecular 
interactions.  
 
1.5 Integrative genetic and genomic networks to identify drivers of disease 
Integrative network approaches have been used extensively to study 
complex diseases, such as cancer, diabetes, neurological and respiratory 
disorders, and other pathologies with underlying genetic causes. Models of 
regulatory networks have been developed to identify disease specific drivers and 
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recover the broken molecular pathways. For example, an integrative network 
approach has been used to identify genetic nodes important to late-onset 
Alzheimer’s disease, highlighting an immune- and microglia-specific module (B. 
Zhang et al. 2013). Furthermore, regulators of genetic risk of breast cancer have 
been discovered by integrative network analysis (Castro et al. 2016) and the 
regulatory landscape of cancer hallmarks has been previously explored (Emmert-
Streib et al. 2014). In addition, integrative networks have been used to improve 
tumor stratification (Hofree et al. 2013) or identify hyper-mutated pathways 
(Vandin, Upfal, and Raphael 2011; Leiserson et al. 2015). Inferring causality from 
molecular data is a difficult problem, particularly because correlation does not 
imply causality. However, incorporating multiple sources of information may lead 
to a better understanding of the biological mechanisms. 
MicroRNAs are a class of small, noncoding RNAs that repress gene 
expression and protein translation. MicroRNAs (miRNAs) play important roles in 
complex cellular pathways by targeting multiple messenger RNAs (mRNAs) of 
protein coding genes (J. Zhang et al. 2014; Sass et al. 2011; Zafari et al. 2015). 
Inferring condition-specific microRNA activity, may reveal new drivers of disease. 
We aim to characterize the microRNA-mRNA disease-specific regulatory 
networks and identify the underlying genetic factors that lead to this 
dysregulation. 
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1.6 microRNA Sequencing 
This thesis provides new data generated via Next Generation Sequencing 
technology. Particularly, by profiling microRNA expression, new disease 
associated microRNAs are revealed. microRNAs are small RNA molecules (~22 
nucleotides), that are highly conserved across species. In addition, these 
molecules are less degraded than mRNAs due to their shorter length, making 
them a good source of biomarkers (Etheridge et al. 2011). 
Mature microRNAs are single stranded. They originate from a double-
stranded stem-loop structure with two arms, 3p and 5p (Figure 1). The 
endonuclease Dicer cleaves the precursor, generating two mature microRNAs 
that may target different mRNAs and provide different biological functions. 
 
 
Figure 1. The microRNA stem-loop structure. This figure was imported from 
https://en.wikipedia.org/wiki/MicroRNA. 
 
microRNAs present a seed sequence that binds specifically to the 3’ UTR 
region of their mRNA targets, inhibiting protein translation. The seed sequence is 
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a conserved heptametrical sequence, located at positions 2-8 from the mature 
microRNA 5´-end (Figure 2). 
Using the sequencing technology, the abundance level of known 
microRNAs can be estimated. The microRNA reads are aligned to human 
genome using short reads aligners, such as Bowtie (Langmead et al. 2009), and 
annotated using existing databases, such as miRBase (Kozomara and Griffiths-
Jones 2011). However, the microRNA sequences can present small variations 
that can also be detected by sequencing (Figure 2).  
 
Figure 2. Examples of microRNA sequences: the seed sequence and potential 
position variants.  
 
A sequencing alignment pipeline has been proposed by (Campbell et al. 
2015). This tool aligns and normalized the short reads, providing several 
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statistics to evaluate the quality of the data. Details about the sequencing 
protocol and sequencing data analysis are provided in the following chapters. 
However variability in microRNA expression can be caused by different technical 
artifacts of the sequencing protocol or platform. Therefore, it is very important to 
use proper control in microRNA expression analysis (Baker 2010). 
Previous studies have also used small RNA sequencing to reveal disease 
associated microRNAs and characterized their role in cancer and other important 
cellular processes (Farazi et al. 2011; Sandhu and Garzon 2011; He and Hannon 
2004; Bartel 2004). This thesis provides new molecular insights of microRNA 
profiles in lung cancer, ILD and COPD. 
 
1.7 Dissertation Aims 
1.7.1 Aim 1: Alterations in bronchial airway microRNA expression for lung cancer 
detection 
First, we aim to characterize the microRNA expression field in the airways 
of ever smokers with lung cancer, and identify disease associated microRNAs.  
In addition, we explore the clinical utility of bronchial microRNA data for 
lung cancer detection in ever smokers. By incorporating microRNA expression 
into an existing mRNA biomarker we significantly improve the performance 
(AUC) in an independent test set. 
The results and the methods of aim 2 are presented in detail in Chapter 2. 
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1.7.2 Aim 2: Biomarker discovery and visualization   
We generalized the biomarker discovery process, and developed a 
visualization tool for biomarker selection. We built upon an existing biomarker 
discovery pipeline, rabbit: an R Application for Building Biomarkers in 
Transcriptomic data, and created a web-based interface to visualize the 
performance of multiple predictors.  
The “visualization” component is the key to sorting through a thousand 
potential biomarkers, and developing clinically useful molecular predictors.  
The proposed visualization software was developed using R-Shiny and it 
is currently available as an open source tool 
(https://github.com/anabrandusa/rabbitGUI). This project is presented in detail in 
Chapter 3. 
 
1.7.3 Aim 3: Integrative analysis to identify microRNA drivers of COPD and ILD 
The molecular events leading to the development of COPD and ILD are 
poorly understood. We hypothesized that integrative genetic and expression 
networks may reveal novel miRNA mediators of genetic factors.  
We built condition specific integrative networks using a causality inference 
test for predicting SNP-miRNA-mRNA interactions, and identified potential 
microRNA drivers of these lung diseases. 
Chapter 4 describes the methodology and the results of this aim. 
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CHAPTER TWO 
Alterations in bronchial airway microRNA expression for lung cancer 
detection 
 
2.1 Introduction 
Based on the National Lung Cancer Screening Trial (NLST) results (Team 
2011), we are currently screening high-risk smokers with annual CT scans of the 
chest, which is leading to an increase in the number of pulmonary lesions being 
discovered. Once a pulmonary lesion is identified, physicians must decide 
between CT surveillance vs. airway/lung biopsy, an assessment that is based on 
pretest risk of disease, comorbidities and patient preference. When biopsy is 
required, the approach can include bronchoscopy, transthoracic needle biopsy 
(TTNB), or surgical lung biopsy (SLB). The choice among these procedures is 
determined on the basis of considerations such as lesion size and location, the 
presence of adenopathy, the risk associated with the procedure, and local 
expertise.  
While bronchoscopy is relatively safe (less than 1% of procedures 
complicated by pneumothorax (Tukey and Wiener 2012)), this procedure is 
limited by its sensitivity (from 34 to 88%), depending on the location and size of 
the lesion (Rivera, Mehta, and Wahidi 2013). Even with newer bronchoscopic 
guidance techniques, the sensitivity for the detection of lung cancer is below 70% 
for peripheral lesions (Wang Memoli, Nietert, and Silvestri 2012).  
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A nondiagnostic bronchoscopy in this setting leads to a clinical dilemma 
as to which of these patients should undergo further invasive diagnostic testing 
(TTNB or SLB). To facilitate this clinical decision, a gene expression-based 
classifier that distinguishes between smokers with and without lung cancer using 
mRNA isolated from cytologically normal cells in the mainstem bronchus has 
been proposed (Whitney et al. 2015; Silvestri et al. 2015).  
In this work, we extend the airway molecular field of injury concept to 
microRNA expression. MicroRNAs are a class of small, noncoding RNAs that 
repress gene expression and protein translation of their target genes by binding 
to the 3’ UTR complementary strands. This regulatory role is key to cellular 
function and can be leveraged to gain insight into the response to exposures and 
even pathogenesis of disease. In addition, compared to mRNAs, microRNAs are 
thought to be more stable molecules, making them more easily measured in 
degraded tissues (Etheridge et al. 2011).  
Previous studies have shown that smoking alters the expression of 
microRNAs in the bronchial airway epithelium (Perdomo et al. 2013; Schembri et 
al. 2009). We hypothesize that bronchial microRNA expression changes may 
also be associated with the presence of lung cancer and that integrating 
microRNA with gene expression could improve lung cancer detection. 
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2.2 Results 
2.2.1 Patient population 
Over 1000 current and former smokers with suspected lung cancer were 
enrolled in the Airway Epithelial Gene Expression in the Diagnosis of Lung 
Cancer (AEGIS) trials (Whitney et al. 2015; Silvestri et al. 2015). 
microRNA expression was profiled via small RNA sequencing for 347 
patients (194 cancer-positive and 153 cancer-negative subjects) from AEGIS-1 
and AEGIS-2 trials. Of the 347 samples, 341 passed the sequencing quality 
control filter. Details about the sequencing protocol and quality control are 
provided in subsections 2.3.2 and 2.3.3.   
We assigned 138 (~ 40%) samples from AEGIS-1 to be used as a 
discovery set (Table 1); these samples were drawn exclusively from the training 
set previously used to develop the gene expression classifier (Whitney et al. 
2015; Silvestri et al. 2015). The remaining 203 samples comprise our test set 
(Table 1) and consist exclusively of samples from the AEGIS-1 (n = 133) and 
AEGIS-2 (n=70) test sets that were previously used to validate the gene 
expression classifier (Silvestri et al. 2015).  
The demographics data for the discovery cohort (138 samples) and the 
test set (203 samples) is presented in Table 1. Except for cancer status, the 
other clinical variables are not significantly different between the two datasets. 
Furthermore, cancer status is significantly associated with age in the discovery 
set and pack-years in the test set (Table 2).  
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 Discovery set 
n=138 
Test set 
n=203 
Cancer Status (n) * Lung Cancer 88 103 
Benign Disease 50 100 
Gender (n) 
Females 62 84 
Males 76 119 
Age (SD; n) 59 (11; 138) 59 (10; 203) 
Smoking Status (n) 
Current 46 88 
Former 92 115 
Cumulative Smoke Exposure - pack-yr. (SD; n) 36 (24; 137) 37 (29; 199) 
 
Race (n) 
White 109 149 
Black 24 46 
Unknown 5 8 
 
Lesion Size (n) 
<3cm 52 71 
>=3cm 58 91 
Infiltrate 15 31 
Unknown 13 10 
 
 
 
 
 
Histology (n) 
NSCLC 72 79 
 
NSCLC 
Stage 
I 11 16 
II 3 5 
III 15 19 
IV 29 26 
Not specified 14 13 
NSCLC 
Subtype 
Adenocarcinoma 31 34 
Squamous 27 25 
Large-cell 2 4 
Not specified 78 140 
SCLC 16 21 
SCLC Stage Limited 4 8 
Extensive 8 12 
Not specified 4 1 
Uncertain Histology 0 3 
 
Diagnosis of Benign 
Disease (n) 
 
 
Resolution or Stability 11 26 
Alternative Diagnosis 39 74 
 
Type of 
Alternative 
Diagnosis 
Sarcoidosis  9 17 
Inflammation  3 2 
Fibrosis 1 1 
Infection 8 14 
Other Alternative 
Diagnosis 
18 40 
Table 1. Patient demographics table. n indicates number of patients with 
available clinical data; SD indicates standard deviation; * p-value < 0.05 by 
Fisher’s Exact Test.  
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Discovery set 
n=138 
Test set  
n=203 
Lung 
Cancer 
n=88 
Benign  
n=50 p 
Lung 
Cancer 
n=103 
Benign  
n=100 p 
Gender 
Females 25 37 
0.84 
38 46 0.2 
Males 63 13 65 54  
Age (SD; n) 61  (10; 88) 
56 
(13; 50) 0.01 
60  
(9; 103) 
58  
(12; 100) 0.29 
Smoking 
Current 32 14 
0.35 
47 41 
0.57 Former 56 36 56 59 
Cumulative Smoke 
Exposure - pack-yr. (SD; 
n) 
38  
(22; 88) 
33  
(27; 49) 0.2 
40  
(28; 102) 
32  
(30; 97) 0.05 
Race 
White 69 40 
0.98 
74 75 
0.8 Black 15 9 26 20 
Unknown 4 1 3 5 
 
Lesion 
Size 
<3cm 30 22  
 
4∙10-4 
20 51  
 
8∙10-14 
>=3cm 47 11 73 18 
Infiltrate 4 11 6 25 
Unknown 7 6 4 6 
Table 2. The association of cancer status with other clinical variables. p-values 
indicating the association of cancer with gender and smoking status were 
computing using a Fisher’s exact test; p-values indicating the association of 
cancer with age and cumulative smoke exposure were computed using a 
Student’s t-test; n indicates number of patients with clinical data available; SD 
indicates standard deviation. 
 
2.2.2 Identifying smoking-associated microRNAs in airway epithelium 
Previous work has shown that cigarette smoke creates a molecular field of 
injury throughout the airway, and specifically that microRNA expression is altered 
with tobacco smoke exposure (Schembri et al. 2009; Powell et al. 1999; Wistuba 
et al. 1997; Franklin et al. 1997; Guo et al. 2004; Miyazu 2005; Spira et al. 2004). 
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We therefore used the ability to detect microRNAs with smoking associated 
expression as a positive control for the quality of the microRNA expression data.  
A set of 28 microRNAs were previously proposed as modulators of gene 
expression changes in airway epithelium (Schembri et al. 2009), with most of 
them (n=23) being down-regulated in current smokers compared to never 
smokers. We found that these down-regulated microRNAs induced by smoking 
were significantly negatively enriched among current smokers (q<0.001), in both 
the discovery (n=138) and the test (n=203) sets (Figure 3). 
 
Figure 3. Enrichment of known smoking related microRNAs by GSEA. The set of 
23 known smoking-induced down-regulated microRNAs are significantly 
negatively enriched among current smokers (q<0.001). 
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In addition, we identified significantly differentially expressed microRNAs 
between current and former smokers by linear regression. The top 30 
differentially expressed microRNAs in the discovery set (q<0.01) are shown in 
Figure 4. Among these, we found microRNAs whose expression has been 
previously associated with smoking, such as miR-218, miR-365, miR-30a and 
miR-99a (Schembri et al. 2009). 
 
Figure 4. Significantly differentially expressed microRNAs between current and 
former smokers (q<0.01). Some of these microRNAs have been previously 
associated with smoking status, such as miR-218, miR-365, miR-30 and miR-
99a. 
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2.2.3 Identifying cancer-associated microRNAs in airway epithelium 
Using the discovery set (n=138), we identified four significantly 
differentially expressed microRNA isoforms between patients with and without 
cancer by linear regression (p<0.002, q<0.2), miR-146a-5p, miR-324-5p, miR-
223-3p, 5p. The expression profiles of these microRNAs are shown in Table 3 
and Figure 5. Each of these miRNA has previously been shown to have tumor-
suppressor-like activity (Chen et al. 2013; Labbaye and Testa 2012; Li et al. 
2013; Nian et al. 2013). Consistent with these previous observations, we find that 
these microRNAs were down-regulated in the bronchial airway of patients with 
cancer. 
 
microRNA miRBase ID p-value q-value t-statistic direction in cancer 
hsa-miR-324-5p MI0000813_MIMAT0000761 0.0007 0.125 -3.49 DOWN 
hsa-miR-223-3p MI0000300_MIMAT0000280 0.0007 0.125 -3.47 DOWN 
hsa-miR-146a-5p MI0000477_MIMAT0000449 0.0008 0.125 -3.43 DOWN 
hsa-miR-223-5p MI0000300_MIMAT0004570 0.0016 0.184 -3.23 DOWN 
Table 3. Cancer-associated bronchial microRNAs (p<0.002, q<0.2). 
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Figure 5. Bronchial microRNAs significantly differentially expressed between 
cancer-positive and cancer-negative patients. (a) Expression of hsa-miR-146a-5p 
(p=0.0008, q=0.125) (b) Expression of hsa-miR-324-5p (p=0.0007, q=0.125) (c) 
Expression of hsa-miR-223-3p (p=0.0007, q=0.125) (d) Expression of hsa-miR-
223-5p (p=0.0016, q=0.184). 
 
2.2.4 Identifying microRNA-mRNA relationships 
MicroRNAs generally lead to the degradation of the mRNAs to which they 
bind. Therefore, we expect a microRNA with functional variation in expression to 
(a) (b)
(c) (d)
hsa-miR-324-5p
p=0.0007
hsa-miR-146a-5p
p=0.0008
hsa-miR-223-3p
p=0.0007
hsa-miR-223-5p
p=0.0016
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be negatively correlated with the expression of its gene targets. We found that 
the distribution of the correlation coefficients of each cancer-associated 
microRNA and its predicted mRNA targets (binding site predicted targets from 
Targetscan) is significantly more negative than the null distribution (p<10-9) 
(Figure 6). 
To begin to understand the potential biological impact of the cancer-
associated expression of the microRNA, we further evaluated the relationships 
between their gene targets and cancer. From the binding site predicted targets 
(Targetscan), we identified the genes whose expression is significantly negatively 
correlated (correlation q<0.1) with the cognate microRNA. These negatively 
correlated targets of each of the four microRNA isoforms were significantly 
positively enriched with cancer status (q<0.001) by Gene Set Enrichment 
Analysis (GSEA) (Subramanian et al. 2005) (Figure 7). In addition, the set of 
genes regulated by these microRNAs (254 in total) is enriched by DAVID 
(Huang, Sherman, and Lempicki 2009) for cancer-associated pathways, such as 
signaling pathways regulating pluripotency of stem cells (p=0.001), pathways in 
cancer (p=0.007), TGF-beta signaling pathway (p=0.035), Ras signaling pathway 
(p=0.043).  
Furthermore, we were able to validate in the test set the microRNA-mRNA 
relationships identified in the discovery set for all four isoforms. The correlation 
coefficients of each cancer-associated microRNA and its predicted mRNA targets 
(binding site predicted targets from Targetscan) are significantly more negative 
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than the null distribution (p<10-7) (Figure 8). In addition, the negatively correlated 
and predicted targets identified in the discovery set were significantly positively 
enriched with cancer status in the test set for each of the four isoforms; GSEA 
results are shown in Figure 9. 
 
Figure 6. The correlation with the predicted targets in the discovery set is 
significantly negative by a Kolmogorov-Smirnov test. The null distribution is 
represented in blue; the distribution of microRNA-mRNA correlations for each 
microRNA is represented in magenta. 
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Figure 7. The negatively correlated and predicted gene targets of the four 
differentially expressed microRNA isoforms are enriched in the discovery set by 
GSEA. (a) miR-146a-5p (50 genes, GSEA q<0.001); (b) miR-324-5p (43 genes, 
GSEA q<0.001) (c) miR-223-3p (89 genes, GSEA q<0.001) (d) miR-223-5p (72 
genes, GSEA q<0.001). 
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Figure 8. The correlation with the predicted targets in the test set is significantly 
negative by a Kolmogorov-Smirnov test. The null distribution is represented in 
blue; the distribution of microRNA-mRNA correlations for each microRNA is 
represented in magenta. 
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Figure 9. The negatively correlated and predicted gene targets of the four 
differentially expressed microRNA isoforms in the discovery set are also enriched 
in the test set by GSEA. (a) miR-146a-5p (50 genes, GSEA q<0.001); (b) miR-
324-5p (43 genes, GSEA q<0.001) (c) miR-223-3p (89 genes, GSEA q<0.001) 
(d) miR-223-5p (72 genes, GSEA q<0.01). 
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2.2.5 Bronchial miR-146a-5p improves lung cancer diagnosis 
We next sought to assess whether bronchial microRNA expression could 
add to the performance of a mRNA biomarker for lung cancer we previously 
identified (Whitney et al. 2015). Using the training set samples, we used logistic 
regression to build five cancer-prediction models:  one model contained the 
mRNA biomarker score alone, the other four models contained the mRNA 
biomarker score in combination with one of the four microRNAs we identified as 
having significant cancer-associated expression.  
Next, we compared the ROC-curve AUC of the mRNA biomarker alone to 
the four microRNA-containing models using a test set comprised of AEGIS-1 and 
AEGIS-2 samples that are independent of the AEGIS-1 samples used to identify 
the four microRNAs with cancer associated expression. The demographic data of 
the test cohort is provided in Table 1 and Supplementary Table 1.  We found that 
adding miR-146a-5p to the mRNA biomarker improved the AUC from 0.66 to 
0.71 (p=0.025), as shown in Figure 10.  
The AUC of biomarkers incorporating either miR-324-5p or either of the 
two isoforms of miR-223 was not significantly different than the AUC of the 
mRNA biomarker alone (p>0.25). 
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Figure 10. ROC AUC. miR-146a-5p significantly improves prediction of the gene-
expression biomarker (p=0.025). The AUC increases from 0.66 (green) to 0.71 
(blue). 
 
2.3 Methods 
2.3.1 Selection of patients 
As previously described, over 1000 current and former smokers 
undergoing bronchoscopy for suspected lung cancer were enrolled in the Airway 
Epithelial Gene Expression in the Diagnosis of Lung Cancer (AEGIS) trials, two 
independent, prospective, multicenter, observational studies (registered as 
NCT01309087 and NCT00746759) (Whitney et al. 2015; Silvestri et al. 2015). 
Exclusion criteria for patients enrolled in AEGIS trials were age less than 21 
years, no history of smoking (defined as having ever smoked <100 cigarettes), 
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and a concurrent cancer diagnosis or history of lung cancer. All study protocols 
were approved by the institutional review board at each medical center and 
written informed consent was obtained from all patients prior to enrollment. 
In this study, we profiled microRNA expression via small RNA sequencing 
for 347 patients. We were limited by patients with a benign diagnosis and 
matched them approximately 1:1 with patients diagnosed with lung cancer. 
Moreover, we attempted to balance the groups for smoking status, cumulative 
smoke exposure (pack-years), gender, and age. For all of the samples selected 
for small RNA sequencing, gene expression profiling of the large RNA fraction 
had been performed previously using Affymetrix Human Gene 1.0 ST arrays 
(Whitney et al. 2015; Silvestri et al. 2015) and was available for data integration. 
2.3.2 High-throughput sequencing of small RNA 
Based on previous work on the effect of multiplexing on microRNA 
expression quantitation (Campbell et al. 2015), we sequenced 347 samples in 
three batches by multiplexing 12 samples per lane on an Illumina HiSeq 2000.  
200 ng of total RNA from each sample was used for library preparation.  
The TruSeq Small RNA Sample Prep Kit (Illumina) was used for the first 
batch, while the NEBNext Multiplex Small RNA Library Prep Set (Illumina) was 
used for the second and third batches. RNA adapters were ligated to 3’ and 5’ 
ends of the RNA and the adapter-ligated RNA was reverse transcribed into 
single-stranded cDNA. The RNA 3’ adapter was designed to target microRNAs 
and other small RNAs that have a 3’ hydroxyl group resulting from enzymatic 
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cleavage by Dicer or other RNA processing enzymes. The adapter used for the 
first batch has the following sequence: TGGAATTCTCGGGTGCCAAGG, while 
the one used for the second and the third batches has the following sequence: 
AGATCGGAAGAGCACACGTCT. 
The cDNA was then amplified by PCR, using a common primer and a 
primer containing one of 12 index sequences. The introduction of the six-base 
index tag at the PCR step allowed multiplexed sequencing of different samples in 
a single lane of a flowcell. A 0.5% PhiX spike-in was also added in all lanes for 
quality control.  Each multiplexed library was hybridized to one lane of the two 8-
lane High-Output single-read flow cells on a cBot Cluster Generation System 
(Illumina) using TruSeq Single-Read Cluster Kit (Illumina).  The clustered flowcell 
was loaded onto a HiSeq 2000 sequencer for a multiplexed sequencing run 
which consists of a standard 36-cycle sequencing read with the addition of a 7-
cycle index read. 
2.3.3 MicroRNA alignment and quality control 
To estimate microRNA expression we used a small RNA sequencing 
pipeline previously described (Campbell et al. 2015). Briefly, the 3′ adapter 
sequence was trimmed using the FASTX toolkit. Reads longer than 15 nt were 
aligned to hg19 using Bowtie v0.12.7 (Langmead et al. 2009) allowing up to one 
mismatch and alignment to up to 10 genomic locations.  
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MicroRNA expression was quantified by counting the number of reads 
aligning to mature microRNA loci (miRBase v20) using Bedtools v2.9.0 (Griffiths-
Jones 2004; Quinlan and Hall 2010). 
Figure 11 illustrates the number of reads and Figure 12 shows the 
mismatch distribution of aligned reads. 
 
Figure 11. Alignment overview. An overview plot showing the total number of 
reads, the number of reads after filtering out adapter-only reads, the number of 
reads after size selection, the number of reads aligned, and the number of reads 
aligning to microRNA precursors for each sample. 
  30 
 
Figure 12. Mismatch distribution. The different number of mismatches are 
indicated by the different colors (red is 0; orange is 1). 
 
MicroRNA counts within each sample were normalized to log2 RPM values 
by adding a pseudocount of one to each microRNA, dividing by the total number 
of reads that aligned to all microRNA loci within that sample, multiplying by 1 × 
106, and then applying a log2 transformation (Campbell et al. 2015). 
Next, we examined the distribution of read lengths present in each sample 
to ensure that the sequences we observed were of the proper length for 
microRNA. The read length distribution ought to follow a normal distribution with 
a mean of 22 bases. We filtered out samples whose distribution had an 
abundance of reads well below or above the mean of 22 bases (with less than 
one million reads aligned to 22 read length), indicating that the sample was not 
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properly sequenced, the adapters were improperly trimmed, or the sample was of 
poor quality (Figure 13). Six such samples were removed, leaving 341 samples 
included in the downstream analysis.  
 
Figure 13. The distribution of lengths of aligned reads. Most aligned reads are 
between 20 and 24 nucleotides long and predominantly align to microRNA loci. 
Reads that were not trimmed (35 nucleotides) aligned to mostly to predicted 
tRNA or snoRNA loci. The distribution of lengths of aligned reads of the high 
quality samples shows that most reads are ~22 nucleotides long which is the 
average microRNA length. For the low quality samples, the distribution of aligned 
reads is not centered on the 22 nucleotides length. 
 
Additionally, we removed microRNA loci with a low number of aligned 
reads (less than 20 on average). A total of 463 microRNA loci passed our filter 
and were included in the analysis.  
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Lastly, we applied ComBat (Johnson, Li, and Rabinovic 2007) to 
normalize the microRNA expression in the three different batches. Large scale 
variability in microRNA expression was examined by Principal Components 
Analysis (PCA). No outlier samples were detected using the first two principal 
components. 
2.3.4 Differential expression analysis 
To identify smoking-associated microRNAs, while correcting for 
covariates, we applied an F-test (anova R function) (Chambers 1992) between a 
multiple linear regression (lm R function), with microRNA expression as the 
response variable, and smoking status, age, gender, cancer status, and pack-
years as independent variables, and another multiple linear regression that did 
not include the smoking status as an independent variable. 
Similarly, to identify microRNAs with cancer-associated expression 
patterns in the discovery cohort, while correcting for covariates, we applied an F-
test between a multiple linear regression, with microRNA expression as the 
response variable, and cancer status, age, gender, smoking status, and pack-
years as independent variables, and another multiple linear regression that did 
not include the cancer status as an independent variable. 
The p-values were adjusted for false discovery rate using Benjamini-
Hochberg FDR  (Benjamini and Hochberg 1995), and were denoted with q-value. 
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2.3.5 Identifying microRNA-mRNA relationships 
We analyzed the correlations between the differentially expressed 
microRNAs and their targets as predicted in the Targetscan database (Lewis, 
Burge, and Bartel 2005). Correlation coefficients were calculated using Pearson’s 
product-moment coefficient. For each microRNA, we compared the resulting 
distribution of correlation coefficients to the distribution of correlation coefficients 
between the microRNA and all the genes that have not been predicted to be 
targeted by it in Targetscan using the Kolmogorov-Smirnov (KS) test.  
Next, we tested whether the negatively correlated targets (correlation 
FDR<0.1) of each differentially expressed microRNA are enriched among the 
genes whose expression is associated with cancer status by Gene Set 
Enrichment Analysis (GSEA) (Subramanian et al. 2005). The genes were ranked 
by the t-statistic of a linear regression, with gene expression as the response 
variable and cancer status, age, gender, smoking status, and pack-years as the 
independent variables. 
2.3.6 Improving the gene-expression classifier by incorporating the expression of 
microRNA 
First, we calculated the prediction scores of the mRNA classifier (Whitney et al. 
2015; Silvestri et al. 2015) using the subset of samples with matched mRNA and 
microRNA data. Then, for each cancer-associated microRNA, we integrated the 
mRNA classifier score with the microRNA’s expression using logistic regression 
(cv.glmnet function from glmnet R package,  
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https://cran.r-project.org/web/packages/glmnet/index.html). Figure 14 
summarizes the method. 
The coefficients of the logistic regression were determined in the 
discovery set and the performance of fully specified models was evaluated in the 
independent test set samples.  
Classification performance was assessed using the area under the 
receiver operating characteristic curve (ROC AUC). The statistical significance of 
the AUC improvement was computed by DeLong test (DeLong, DeLong, and 
Clarke-Pearson 1988) from the pROC R package (Robin et al. 2011).  
 
Figure 14. miR-146a-5p expression is integrated with the clinico-genomic score 
of the existing gene expression classifier by logistic regression. The logistic 
regression model was implemented using cv.glmnet() function from glmnet R 
package. By training the weights of the logistic regression in the discovery set, 
we obtained the following values: β0 = 1.85, β1 = 4.39, β2 = -0.37. 
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2.4 Discussion 
CT screening of high-risk smokers for lung cancer has led to an increase 
in the number of lesions detected. When routine clinical diagnostic workup is 
inconclusive, profiling mRNA in the bronchial airway epithelium has been shown 
to improve detection (Whitney et al. 2015; Silvestri et al. 2015; Spira et al. 2007). 
In this study, we expanded on this concept by profiling microRNA expression in 
the bronchial airway to identify lung cancer associated microRNAs that, in 
combination with mRNA, have the potential to aid in the detection of disease.  
Prior studies have demonstrated that microRNAs have aberrant 
expression, mostly down-regulated, in tumors compared to normal tissue, and 
have been associated with tumor suppression, cell differentiation, cell signaling, 
and apoptosis (Lu et al. 2005).  Furthermore, profiling microRNA in the bronchial 
airway, a less invasive site than tumor tissue, has revealed microRNA expression 
alterations associated with exposure to tobacco cigarette smoke10. In this study, 
we confirm that microRNA expression changes occur in the airway of current 
smokers when compared to formers, and importantly, show that the airway field 
of injury for lung cancer is reflected in microRNA expression differences. 
We identified four microRNA isoforms (miR-146a-5p, miR-324-5p, miR-
223-3p, miR-223-5p) that have altered expression in the airway epithelium of 
patients with lung cancer.  Similar to findings in tumor tissue, these microRNAs 
were all down-regulated in cancer patients.  Intriguingly, all these microRNAs 
have previously been implicated in tumor suppressive pathways. Specifically,  
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miR-146a has been previously shown to inhibit cell growth, migration and EGFR 
signaling (Labbaye and Testa 2012; Kumaraswamy et al. 2015; Chen et al. 
2013), while inducing apoptosis. Furthermore, miR-146a/b expression levels 
have been shown to be significantly elevated during senescence (a cellular 
program that irreversibly arrests the proliferation of damaged cells) (Bhaumik et 
al. 2009). miR-223 has been shown to function as a tumor suppressor in the 
Lewis lung carcinoma cell line by targeting insulin-like growth factor-1 receptor 
and cyclin-dependent kinase-2 (Nian et al. 2013); and miR-324 has been 
associated with nasopharyngeal cancer (Li et al. 2013). While microRNA 
expression differences have already been well documented in tumors, we are 
showing for the first time that the expression of microRNAs with cancer-related 
functions is altered in the bronchial airway of lung cancer patients. 
To begin to determine if the altered expression of these cancer-associated 
microRNAs has a functional impact on the airway epithelium, we demonstrated 
that the expression of mRNAs which are predicted targets of these microRNAs is 
significantly negatively correlated with the expression of the cancer-associated 
microRNAs suggesting that the expression of downstream genes is induced as a 
consequence of the cancer-dependent loss of microRNA expression.   
Moreover, predicted targets with negatively correlated expression profiles 
are enriched for genes involved in processes important for cancer, such as the 
pluripotency of stem cells, TGF-beta and Ras signaling pathways. Among the 50 
significantly negatively correlated predicted targets of miR-146a-5p, we found 
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APPL1 (adaptor protein, phosphotyrosine interaction, PH domain and leucine 
zipper, DCC-interacting protein 13-alpha). The protein encoded by APPL1 gene 
binds to many other proteins, including PIK3CA, RAB5A, DCC, AKT2, 
adiponectin receptors, and proteins of the NuRD/MeCP1 complex, which are 
involved in cell proliferation and crosstalk between adiponectin and insulin 
signaling pathways. Interestingly, we also observed a significantly negative 
correlation between miR-146a-5p and PIK3CA, suggesting that miR-146a-5p 
interacts with PI3K/AKT pathway. In addition to the important role of PI3K/AKT 
pathway in cell death/survival, an increased activity of PI3K has been shown to 
be an early and potentially reversible event in the airway of smokers with 
premalignancy and lung cancer (Singh et al. 2002; Gustafson et al. 2010).  
The correlation of these differentially expressed bronchial microRNAs with 
cancer-associated mRNA targets suggest their role as lung cancer-associated 
regulators of gene expression, and potentially could serve as biomarkers of 
disease. 
We assessed each differentially expressed microRNA’s ability to enhance 
the performance of an mRNA biomarker that had been developed and validated 
using samples from the same cohort5.  We integrated miR-146a-5p expression 
into the mRNA classifier from Whitney et al. (Whitney et al. 2015), and have 
shown that it significantly improves the performance of the lung cancer 
biomarker.  
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In addition, we examined the added value of the other three cancer-
associated microRNA isoforms and found that they did not improve the 
performance. Interestingly, we believe that miR-223-3p and miR-223-5p did not 
add to the biomarker performance because one of their targets (SNCA) is a 
member of the mRNA classifier, thus miR-223 expression might be redundant 
with SNCA expression levels and not capable of adding new information about 
the likelihood of lung cancer to the biomarker. If this hypothesis is correct, it 
would suggest that miR-146a adds to the biomarker’s performance because the 
mRNA biomarker does not already capture miR-146a-related information.  
In this study we demonstrate for the first time the presence of a microRNA 
field of injury in the bronchial airway for lung cancer. We identified microRNA that 
are known to play a role in cancer-related processes, and importantly, we 
demonstrate that a multi ‘omics data integration approach may improve 
prediction. Future work includes extending this biomarker development approach 
to even less invasive sampling sites (e.g. nasal brushings), which has the 
potential to expand the clinical impact of molecular biomarkers. 
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CHAPTER THREE 
Biomarker discovery and visualization 
 
3.1 Introduction 
Based on the methods described by MAQC project (MAQC Consortium et 
al. 2006), our group has proposed a pipeline for biomarker discovery, rabbit: an 
R Application for Building Biomarkers in Transcriptomic data (J. Perez-Rogers, 
PhD Thesis, 2016; https://github.com/jperezrogers/rabbit). The software runs 
several combinations of binary class predictors in cross-validation on a given 
normalized gene-expression dataset. Figure 15 illustrates the four modules of the 
biomarker pipeline that correspond to the main steps of the biomarker discovery 
process:  
1. feature filtering (unsupervised); 
2. feature ranking (supervised); 
3. biomarker size selection; 
4. classification. 
This tool has been developed using a modular approach based on object 
oriented programming paradigm. Therefore, the framework can be extended to 
other algorithms as well. The current version of the pipeline includes 840 
combinations of methods, tested in cross-validation. However selecting the best 
biomarkers from almost a thousand potential predictors remains an open 
question. Some combinations of models may be biased towards noisy patterns 
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that are specific to a particular dataset. By simply selecting the predictor with the 
highest ROC AUC, the user may deal with overfitting and not necessarily with the 
most robust biomarker. In this work we propose a methodology to sort through 
almost a thousand potential biomarkers. Our approach is based on a graphical 
interface that visually guides the user through the entire biomarker selection 
process. 
 
Figure 15. The biomarker discovery pipeline runs all available combinations of 
feature filters, feature ranking, biomarker sizes and classifiers in cross-validation. 
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We propose rabbitGUI a new web-based graphical interface that helps to 
evaluate the performance of all statistical and machine learning methods tested 
in cross-validation by rabbit. This tool has been implemented as an R-Shiny 
application and the code is available as open-source 
(https://github.com/anabrandusa/rabbitGUI). The functionalities of rabbitGUI will 
be detailed in the following sections. 
 
3.2 Results 
3.2.1 rabbitGUI: a web-based interface for biomarker discovery 
In this section, a detailed description of rabbitGUI functionalities is 
provided. As a case study, a publicly available dataset from MAQC project (ER+/- 
breast cancer patients (Popovici et al. 2010)) is used. 
 3.2.1.1 Model selection 
Model selection tab is designed to guide the user through the selection of 
the best combination of models in a step-wise manner, following the four main 
steps in the biomarker discovery process: feature filtering, feature ranking, 
biomarker size selection and classification.  
The user can navigate through the four steps using a radio button menu. 
In each step, each method is evaluated across all the possible predictors that 
incorporate that method. If a method performs generally well across all the 
methods in all the other steps, it is considered robust and less likely to over-fit.  
  42 
To provide an evaluation of the prediction results and compare them 
across the different models, the following statistical procedure is applied. 
In each step, we compare the performance (mean ROC AUC) of each 
model across all the possible predictors by ANOVA. If the p-value is significant, 
then we apply a Tukey HSD test to identify the top model groups. The models 
that perform significantly lower than any other models are excluded, and the top 
remaining models are colored in red. The adjusted p-values from the Tukey HSD 
test are provided in a table displayed below the boxplots. 
Figures 16, 17, 18 and 19 illustrate each of the four steps along with a 
summary of the results from the Tukey HSD test.  
Based on these four steps, multiple combination of models may be 
selected. Previous studies have shown that multiple feature selection and 
classification algorithms may produce statistically equally good predictors 
(Popovici et al. 2010; MAQC Consortium et al. 2006). Therefore, the GUI 
provides a table with all selected biomarkers (Figure 20).  
In addition, the GUI displays a summary of the boxplots displayed at each 
step, including the mean, standard deviation, median, minimum and maximum 
values, and 1st and 3rd interquartile values. This information is displayed if the 
user accesses the link below the boxplots: “Boxplot summary (click to display)”. 
This information can be used to further filter the final list of model combinations. 
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Figure 16. Feature filtering. In this example, all four feature filtering methods 
perform similarly well across all the predictors that incorporate them (ANOVA 
p=0.87). 
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Figure 17. Feature ranking. The top feature ranking methods in this case are t-
test, pAUC and signal-to-noise (colored in red). 
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Figure 18. Biomarker size selection. The best biomarker sizes in this case are 
50, 200, 500 features (colored in red). However, we recommend the user to 
consider the minimal size biomarker, since fewer features can be more easily 
translated in a clinically useful test. 
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Figure 19. Selection of the classifier. The best classifiers in this case are random 
forest, naïve bayes, svm and weighted voting (colored in red). 
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Figure 20. Best selected predictors. In this case we found 48 equivalently good 
biomarkers (20 of them are shown above). For the biomarker size we include 
only the smallest set of features that performs the best (in this case 50 features).  
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3.2.1.2 Comparison with random predictions 
The Random mean AUC tab displays the performance of each method in 
each step compared to a random. For the random experiments we apply the 
same methods, using a random shuffle class label of the samples. The results 
generated using the random class label represent a quality control step, 
confirming that the real performance is not a technical artifact. For each step, we 
display the random results below the real performance for each method (Figure 
21).  
 
 
 
Figure 21. Real performance vs. random performance for each method in a step 
(this example shows the feature ranking step). 
 
3.2.1.3 Visualize sample-level prediction scores 
The Prediction scores tab allows the user to navigate through all potential 
biomarkers and visualize the sample-level prediction scores of all cross-
validation runs (Figure 22). The models are sorted by the highest ROC AUC and 
the distribution of the scores are colored differently for the two classes. A 
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selection menu is available for the user to visualize a particular predictor by its 
index or name. 
 
 
 
 
 
 
Figure 22. Visualize sample-level prediction scores for each predictor, for both 
the real and the random shuffle class label tests. 
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3.2.1.4 Visualize heatmap 
 
This tab allows the user to visualize any heatmap, by uploading the 
following files: 
 a .csv file with the expression matrix (samples on the columns and genes 
on the rows); 
 a .csv file indicating the sample phenotype (a column vector with 0/1 for 
each sample, assuming the samples are in the same order as in the 
expression matrix); 
 a .txt file with a list of features (the same format as the feature files 
generated by rabbit). 
Bash scripts that collect the features for each model, across all cross-
validation runs, have been implemented. To visualize all potentially relevant 
features based on the cross-validation results, the union of all selected features 
is considered. More details can be found in the section 3.3.2. 
However, this tab is general and any heatmap can be displayed by the 
user, if the proper inputs are provided (Figure 23). 
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Figure 23. Visualize the heatmap of biomarker features. 
 
3.3 Methods 
3.3.1 Shiny applications 
Shiny is a new package from RStudio that makes it easy to build 
interactive web applications with R (http://rstudio.github.io/shiny/tutorial/). It 
provides automatic binding of inputs and outputs and pre-built widgets that 
facilitates the process of developing user-friendly, interactive, and powerful 
applications.  
The main features of Shiny apps are the following: 
 Build useful web applications with only a few lines of code; 
 Shiny applications are automatically interactive; 
 Outputs change instantly as users modify inputs, without requiring a 
reload of the browser; 
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 Shiny user interfaces can be built entirely using R, or can be written 
directly in HTML, CSS, and JavaScript for more flexibility; 
 Shiny works in any R environment (Unix, Windows or Mac); 
 Pre-built output widgets for displaying plots, tables, and R objects. 
A Shiny app is based on client-server architecture, where the client issues 
requests to the server based on the user inputs. The information provided by the 
server is then displayed by the client. 
In this work leverage the flexibility of Shiny package and develop a usr-
friendly GUI to evaluate and interact with the outputs of rabbit biomarker 
discovery package. 
3.3.2 Installing rabbit, rabbitGUI and dependencies 
rabbit pipeline is based on caret package, and it requires R>=3.2.3. In 
order to run rabbit pipeline with all the default models, the following R 
dependencies are required: pbkrtest (R >= 3.2.3); car (R >= 3.2.0); nlme (R >= 
3.0.2); devtools; multtest; impute; samr; e1071; randomForest; klaR; kernlab; 
glmnet; limma; genefilter. 
After these dependencies are installed, the user can install rabbit from 
github, as following: install_github("jperezrogers/rabbit", ref="master"). 
rabbitGUI does not require the installation of rabbit package, as long as 
the proper inputs are provided (see subsection 3.3.3 for more details). However, 
it requires that the following database of model names and indices is present in 
the directory specs, under the local directory of rabbit source code. 
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This database can be saved from rabbit: stockPipeline$getModelSpecs(). 
Alternatively, if rabbit package is not installed, the file specs.csv can be 
found from the following web address: 
https://github.com/anabrandusa/rabbitGUI/tree/master/rabbitGUI_code/specs. 
In addition, in order to run rabbitGUI, the following R dependencies need 
to be installed: shiny; DT; pROC; ROCR; markdown; gplots. 
The Shiny app can be downloaded from the following web address: 
https://github.com/anabrandusa/rabbitGUI/tree/master/rabbitGUI_code, and 
launched by running app.R script. 
The application can run on any system with an R environment (Unix, 
Windows or Mac). Online details about the GUI are available at the following web 
address: https://github.com/anabrandusa/rabbitGUI/blob/master/README.md. 
3.3.3 Processing and aggregating the classification results from rabbit pipeline 
rabbit biomarker discovery tool is able to run multiple models in cross-
validation in parallel environment. It has been configured to run in parallel on an 
SGE cluster using qsub. The function run takes as inputs an object that defines 
the pipeline’s configuration, an expression matrix, a binary phenotype vector, the 
current cross-validation iteration, the output directory, and other parameters 
(https://github.com/jperezrogers/rabbit/tree/master/vignettes). The function is 
submitted an available computing node for each iteration, using qsub.  
The output consists of n directories (corresponding to n cross-validation 
iterations). Each of these directories contain m other directories (corresponding 
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to the outputs of m tested predictors). For each predictor two output files are 
generated: predictions.txt (the sample-level prediction scores) and features.txt 
(the list of features used for classification). 
The role of rabbitGUI is to summarize the overall performance of all 
models and iterations. To standardize the inputs of the web-based interface, the 
outputs from rabbit pipeline are processed as following. For each iteration and 
each model, ROC AUC is computed. This can be done in parallel for each 
iteration, by running process.rabbit.outputs.sh. The results are then merged into 
one file by create.shiny.inputs.sh. The ROC AUC across n cross-validation 
iterations is computed in two different ways: 
 mean AUC across all iterations; 
 AUC of all test samples in all iterations. 
 The getFeaturesInParallel.sh submits a qsub job for each model, 
collecting all features from all cross-validation iterations for that model. Then by 
running getFeatureUnion.sh, a file containing the union of all features from all 
iterations is generated for each model. This file can be uploaded into rabbitGUI to 
visualize the heatmap all features selected in cross validation for a particular 
model.  
All the Bash and R scripts that collect the results from rabbit, compute the 
performance and prepare the inputs for rabbitGUI are available as open source 
(https://github.com/anabrandusa/rabbitGUI/tree/master/prepare_inputs_rabbitGU
I).  
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rabbitGUI inputs are stored under the local directory of the application, in 
data_clasified and data_random folders. Each of these two directories contain 
alldata.csv and aucmeans.csv files.  
The results from data_random are obtained by running rabbit with a 
randomly assigned class of the samples, serving as a quality control of the data 
and methods used. Examples of rabbitGUI input files are provided on github and 
in Figures 24 and 25. 
 
 
Figure 24. alldata.csv file is an input for rabbitGUI and contains the sample-level 
prediction scores of all predictors and all iterations merged in one csv file. 
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Figure 25. aucmeans.csv file is an input for rabbitGUI and contains the ROC 
AUC values of all models, computed across all cross-validation iterations as a 
mean AUC and as the AUC of all test samples in all iterations. The models in the 
table are sorted in descending order by ROCRAUC values. 
 
3.3.4 Biomarker discovery methods available from rabbit and rabbitGUI 
rabbitGUI displays and evaluates the results from all methods tested by 
rabbit pipeline. rabbit is flexible and allows the user to activate and deactivate 
specific methods. In addition, new algorithms can be added to the collection. 
However, this section briefly describes the default models integrated in rabbit 
package and evaluated by rabbitGUI. 
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3.3.4.1 Feature filtering 
This step consists of unsupervised feature filtering methods. The following 
methods select the features that present the most variability across samples, 
having the highest potential to discriminate the data. 
 Median Absolute Deviation (MAD) 
o ranks each feature X by the absolute median deviation across 
samples i=1,…,n: 
MAD(X) = median(abs(Xi-median(X))); 
o selects the top q features; 
o MAD is ran three times independently by default, assigning the 
following q values: 25%, 50% and 75%. 
 Mean-expression 
o compares each feature vector with the vector of mean expression 
across all features; 
o genes with p<0.05 are selected. 
3.3.4.2 Feature selection 
This step is a supervised gene ranking. The features are ranked by their 
ability to discriminate between the two classes. 
 Significance Analysis of Microarrays (SAM) 
o non-parametric statistics; 
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o computes a test statistic for the relative difference in gene 
expression between the two groups, based on permutation analysis 
of expression data, and calculates a false discovery rate; 
o samr() function from samr R package. 
 Moderated t-test and fold change (FC+P) 
o genes are first scored by moderated t-statistic (Smyth 2004), using 
eBayes function from limma R package; 
o genes with a p-value less than 0.05 are selected and then ranked 
by log2 fold-change. 
 T-test 
o standard two-sample t-test assuming equal variances. 
 Partial AUC (pAUC) 
o integrates AUC to a limit p given as parameter (default p=0.1); 
o rowpAUCs() function from genefilter R package; 
 Signal-to-noise 
o defined by (Golub et al. 1999): each feature is ranked by the 
difference in means between the two groups relative to the 
standard deviations within the two groups; 
3.3.4.3 Biomarker size selection 
Using the features ranking described previously, this step selects the top n 
features. In case there are fewer than n features, all features are included. 
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3.3.4.4 Classification 
This step uses the set of features selected by the previous steps applies 
different supervised algorithms for binary classification. 
 Linear discriminant analysis (LDA) 
o finds a linear combination of features that characterizes or 
separates two or more classes; 
o assumes continuous independent variables and categorical 
dependent variable; 
o included in caret R package (method="lda"). 
 Weighted Voting 
o defined by (Golub et al. 1999): this procedure uses a fixed subset 
of genes and  makes  a  prediction on the basis of the expression 
level of these genes in a new sample; each informative gene 
generates a “weighted vote” for one of the classes, with the 
magnitude of each vote dependent on the expression level in the 
new sample and the degree of that gene’s correlation with the class 
distinction; the votes are summed to determine the winning class,   
as   well   as   the prediction score; 
o included in caret R package (function wv.model()). 
 Support Vector Machines (SVM) 
o discriminative classifier defined by a separating hyperplane; an 
SVM model is a representation of the samples as points in space, 
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mapped so that the separate categories are divided by a clear gap 
that is as wide as possible; 
o included in caret R package (method="svmRadial"). 
 Naïve Nayes 
o probabilistic classifier based on applying Bayes' theorem, under the 
assumption that features are independent; 
o included in caret R package (method="nb"). 
 Elastic Net 
o regularized regression method that linearly combines the penalties 
of the lasso and ridge methods for a logistic regression model; 
o included in caret R package (method="glmnet"). 
 K-Nearest Neighbors 
o assigns a sample to the class of its closest neighbor in the feature 
space, based on a defined distance, such as the Euclidian 
distance; 
o included in caret R package (method="knn"). 
 Random Forest 
o selects random subsets of the feature-variables and creates a 
decision tree on each subset by maximizing information gain 
o it classifies the test samples using all trees; the class is assigned 
based on the prediction of the majority of the trees; 
o included in caret R package (method="rf"). 
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3.4 Discussion 
rabbitGUI is an open source GUI for biomarker discovery. The visual 
component is designed to guide the user to select the best predictors from a pool 
of about one thousand model combinations.  
rabbit and rabbitGUI can serve as a user-friendly framework for biomarker 
discovery. The main advantages of this software system are the following: 
 standardized tool for biomarker discovery; 
 provides an easy-to-use GUI for evaluating and interpreting the 
results; 
 availability: free and open source; 
 flexibility: it can be extended by adding new methods and 
visualization components; 
 multi-platform: it can run on different platforms (Unix, Windows or 
Mac); 
 parallelized for SGE cluster. 
 
The framework has been designed to be a user-friendly resource for 
researchers in all fields, including both computational and experimental 
biologists. We plan to further extend both rabbit and rabbitGUI by integrating new 
methods and visualization features.  
Currently, rabbitGUI is a powerful visual resource to interpret and display 
the results generated by rabbit pipeline.  
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In future work, we plan to extend the web-based interface to provide a 
configuration menu for rabbit pipeline and the option to run the application 
interactively from the GUI. 
In addition, we plan to extend this software system to run on a cloud 
computing platform, such as Amazon or Google Cloud Platform, providing quick 
and user-friendly access. We believe this tool will be a valuable resource for the 
translational bioinformatics research community. 
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CHAPTER FOUR 
Integrative microRNA networks reveal potential roles for miR-449/34 family 
in COPD and ILD 
 
 
4.1 Introduction 
Complex diseases arise from a heterogeneous molecular interplay 
between genetic and genomic alterations. Although biological processes, such as 
chronic inflammation, apoptosis, and oxidative stress, have been found to play a 
role in COPD and ILD pathogenesis, knowledge remains limited about the key 
molecular interactions of these diseases (Steiling et al. 2013).  
Several computational approaches have been applied to infer causality 
from biological data, including Bayesian networks (Vignes et al. 2011; Aliferis et 
al. 2010; Dondelinger, Husmeier, and Lèbre 2012), factor graphs (Ng et al. 2012; 
Vaske et al. 2010) and ridge and least absolute shrinkage and selection operator 
(Omranian et al. 2016).  
In 2009, E. Schadt’s group proposed a data driven statistical framework to 
infer mediators of genetic factors associated with quantitative traits. The causality 
is modeled as a “chain” of mathematical conditions that test the strength of the 
associations (Millstein et al. 2009). This approach has been applied to 
characterize the role of microRNAs (miRNAs) within gene regulatory networks 
(Su, Kleinhanz, and Schadt 2011). In this work, we take a similar approach to 
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unravel the miRNA dysregulations that mediate the genetic factors of COPD and 
ILD.  
We profiled miRNA expression from 351 patients from the Lung Genomics 
Research Consortium (LGRC). Previous LGRC GWAS studies have found 
associations of genetic factors with adult lung function (Tang et al. 2014) and 
idiopathic pulmonary fibrosis (Noth et al. 2013). We integrate miRNA expression 
with publicly available SNP and mRNA data.  We first infer causality of the 
molecular associations between SNP, miRNA and mRNA using show that there 
is a difference in the connectivity between the disease networks compared to 
control. The networks capture the differences in miRNA regulation, revealing new 
miRNA drivers of disease.  
 
4.2 Results 
4.2.1 eQTL analysis 
Using the LGRC cohort, we profiled miRNA expression via small-RNA 
sequencing from 351 lung tissue samples from patients with COPD, ILD and 
controls (Table 4).  
By “anchoring” expression data with genetic information, we can identify 
key miRNA regulators of gene expression associated with COPD. Therefore, we 
utilized a subset of the 262 lung tissue samples with profiled miRNA expression, 
as well as publicly available SNP and mRNA data (Table 5). 
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Covariates Control (n=62) ILD (n=144) COPD (n=145) 
Smoking Status ˦ ǂ 2 current,  
38 former,         
19 never,  
3 NA 
5 current,  
85 former,  
50 never,  
4 NA 
8 current,  
129 former,  
6 never,  
2 NA 
Age ǂ 63.1 (12.0) 61.2 (10.2) 64.4 (9.9) 
Pack Years * ˦ ǂ 41.1 (36.6) 26.3 (19.9) 55.9 (39.0) 
Gender 31 males, 
31 females 
78 males, 
66 females 
86 males, 
59 females 
FEV1/FVC * ˦ ǂ 0.77 (0.1) 0.83 (0.1) 0.5 (0.2) 
Percent Emphysema ˦ ǂ 0.7 (1.0) 0.8 (1.7) 16.6 (18.0) 
Table 4. Demographics table of samples with available miRNA and mRNA data. 
*Significantly different between ILD and Control (p<0.05); ˦Significantly different 
between COPD and Control (p<0.05); ǂSignificantly different between ILD and 
COPD (p<0.05); p-values for gender and smoking status were calculated by 
using Fisher’s exact test; p-values for age, pack years, FEV1/FVC and Percent 
Emphysema were calculated by using Student’s t-test. 
 
Covariates Control (n=38) ILD (n=113) COPD (n=111) 
Smoking Status ˦ ǂ 2 current,  
24 former,         
12 never 
4 current,  
71 former,  
38 never 
7 current,  
99 former,  
5 never  
Age 65.5 (11.5) 62.2 (9.2) 63.8 (9.2) 
Pack Years * ǂ 49.9 (40.8) 26.3 (20.4) 55.1 (37.8) 
Gender 22 males,  
16 females 
61 males,   
52 females 
65 males,  
46 females 
FEV1/FVC * ˦ ǂ 0.76 (0.06) 0.83 (0.07) 0.49 (0.24) 
Percent Emphysema ˦ ǂ 0.7 (1.0) 0.74 (1.7) 17.0 (18.3) 
Table 5. Demographics table of samples with available miRNA and mRNA data. 
*Significantly different between ILD and Control (p<0.05); ˦Significantly different 
between COPD and Control (p<0.05); ǂSignificantly different between ILD and 
COPD (p<0.05); p-values for gender and smoking status were calculated by 
using Fisher’s exact test; p-values for age, pack years, FEV1/FVC and Percent 
Emphysema were calculated by using Student’s t-test. 
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Using PLINK (Purcell et al. 2007) we performed an eQTL (expression 
quantitative trait loci) analysis, considering both CIS and TRANS interactions, 
where CIS was defined as <1MB, and including both miRNA and mRNA features. 
We identified all genes and miRNAs associated with a SNP by ANOVA 
while correcting for age, gender, smoking status, and population structure 
(p<0.0005). The number of significant CIS and TRANS eQTLs (p<0.05) identified 
within each group are presented in Figure 26. Most of the associations between 
SNPs and miRNAs are TRANS, and very few are CIS (see section 4.3.4 for the 
definition of CIS/TRANS associations). 
The QQ-plots show significant p-values for both CIS (local) and TRANS 
(distant) associations, in all three groups: COPD (Figure 27), and ILD (Figure 
28), control (Figure 29). 
 
Figure 26. Number of significant eQTLs (p<0.05). 
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Figure 27. QQ-plot in COPD patients. 
 
 
Figure 28. QQ-plot in ILD patients. 
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Figure 29. QQ-plot in control patients. 
 
4.2.1 miR-34/449 family is differentially connected in disease compared to control 
Next, we built integrative networks within the COPD, ILD, and control 
patients using the causality inference test (CIT) (Millstein et al. 2009). CIT 
assesses the hypothesis that a potential mediator between an initial randomized 
variable and an outcome variable is causal for that outcome. Causal and 
independent relationships are defined as series of conditions of associations 
between the three variables, corresponding to SNP, microRNA and mRNA nodes 
(Figure 30).  
Then, we explored the scale-free property of the networks (Barabási and 
Oltvai 2004; Barabasi and Bonabeau 2003) by computing the frequency of node 
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degree in log-scale. As expected, the networks are biologically meaningful, 
presenting a negative linear relationship between the node degree and the 
frequency of node degree in log scale (Figure 31). 
 
Figure 30. Network construction; we select those SNP-miRNA-mRNA triplets 
where the SNP-mRNA relationship is defined by a miRNA mediator. We filter out 
independent relationships and those triplets where the SNP is not associated 
with the miRNA. 
 
 
Figure 31. The CIT networks follow a power law. The negative correlation 
between the frequency of node degree and the node degree indicates that the 
networks are scale-free. 
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Furthermore, we identified the miRNAs predicted to interact with the most 
genes in each network (Table 6).  
 
Top mostly connected 
miRNAs in COPD 
Top mostly connected 
miRNAs in ILD 
Top mostly connected 
miRNAs in Control 
hsa-miR-27a-5p * 
hsa-miR-190b * 
hsa-miR-449b-5p * 
hsa-miR-449a * 
hsa-miR-449c-5p * 
hsa-miR-4423-5p * 
hsa-miR-92b-3p * 
hsa-miR-34c-3p  
hsa-miR-205-5p 
hsa-miR-23a-5p * 
hsa-miR-509-3p-2 
hsa-miR-509-3p-3 
hsa-miR-509-3p-1 
hsa-miR-30a-3p 
hsa-miR-34b-3p * 
hsa-miR-1185-1-3p 
hsa-miR-125b-1-3p 
hsa-miR-654-5p 
hsa-miR-485-5p 
hsa-miR-34c-5p 
 
 
hsa-miR-92b-3p * 
hsa-miR-449a * 
hsa-miR-200a-5p * 
hsa-miR-31-5p * 
hsa-miR-92b-5p * 
hsa-miR-449c-5p 
hsa-miR-200b-3p * 
hsa-miR-31-3p * 
hsa-miR-190b * 
hsa-miR-449b-5p * 
hsa-miR-511-1 * 
hsa-miR-511-2 * 
hsa-miR-34c-5p 
hsa-miR-34c-3p 
hsa-miR-146b-5p * 
hsa-miR-2110 * 
hsa-miR-34b-5p 
hsa-miR-450b-5p 
hsa-miR-200a-3p 
hsa-miR-34b-3p 
 
hsa-miR-21-5p * 
hsa-miR-4802-3p * 
hsa-miR-146a-5p * 
hsa-miR-378c * 
hsa-miR-142-3p * 
hsa-miR-146b-5p * 
hsa-miR-421 * 
hsa-miR-30a-3p 
hsa-miR-378a-5p * 
hsa-miR-378a-3p * 
hsa-miR-330-5p * 
hsa-miR-425-5p * 
hsa-miR-378i * 
hsa-miR-26a-5p-1 * 
hsa-miR-26a-5p-2 * 
hsa-miR-223-5p * 
hsa-miR-191-5p * 
hsa-miR-30a-5p 
hsa-miR-509-3p-2 
hsa-miR-509-3p-3 
hsa-miR-509-3p-1 
hsa-miR-5571-3p 
hsa-miR-301b * 
hsa-miR-766-3p * 
hsa-miR-199b-5p * 
hsa-miR-34a-5p * 
Table 6. Top 20 mostly connected miRNAs in each phenotype. * indicates the 
significant FDR-adjusted p-values (q<0.2) by a Fisher’s exact test that 
determines the difference in the connectivity frequencies between the two 
phenotypes for each miRNA. 
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Dysregulated miRNAs that interact with large gene modules are more 
likely to cause important phenotypic changes. Members of the miR-449/34 family 
were found to be among the top ranked in COPD and ILD networks (Figure 32), 
indicating that miR-449/34 family has a greater impact on gene expression 
regulation in disease compared to control group. 
miR-449 members are located on chromosome 5 and miR-34 members, 
on chromosome 11. However, these miRNAs are known to be co-expressed, 
presenting similar biological functions (Fededa et al. 2016). Members of miR-
34/449 family can promote airway differentiation by repressing the Notch 
pathway (Chevalier et al. 2015; Bae et al. 2012; Lizé, Klimke, and Dobbelstein 
2011). In addition, these miRNAs were found to share an increased number of 
associated genes, as illustrated in Figure 33. 
 
 
Figure 32. Top differentially connected microRNAs in COPD (right) and ILD (left). 
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Figure 33. miR-449/34 modules present an increased number of shared genes 
by Jaccard index. 
 
Furthermore, we observed that the combined set of genes that positively 
correlated with these miRNAs were enriched among genes that increase in 
expression over time when airway basal cells are differentiated at an air-liquid 
interface (ALI) (Ross et al. 2007). Gene enrichment results were significant by 
both GSVA, p<10-3 (Figure 34a) and GSEA, q<0.001 (Figure 35).  
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This set of genes was also associated with genes that are positively 
correlated with airway wall thickening in patients with emphysema, by both 
GSVA, p<10-4 (Figure 34b) and GSEA, q<0.001 (Figure 36). All these results 
suggest that the miR-449/34 family is playing a role in differentiation associated 
with the airway wall thickening phenotypes.  
 
 
Figure 34. Enrichment of miR-449/34 modules by GSVA. (a) Enrichment of miR-
449/34 gene set family with airway cells differentiation by GSVA. The set of 
genes that positively correlated with miR-449/34 family (406 genes) were 
enriched among genes that increase in expression with the airway epithelial cells 
differentiation in COPD; (b) Enrichment of miR-449/34 gene set family with 
increasing airway wall thickness in patients with emphysema by GSVA. The set 
of genes that positively correlated with miR-449/34 family were enriched among 
genes that increase in expression with airway wall thickening of patients with 
emphysema in COPD. 
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Figure 35. Enrichment of miR-449/34 associated genes with airway differentiation 
by GSEA. The set of genes that positively correlated with miR-449/34 family 
were enriched among genes that increase in expression with the airway epithelial 
cells differentiation (q≈0), both in (a) COPD and (b) ILD. Genes were ranked from 
those that increased in expression with time of differentiation (red) to those that 
decreased in expression with time of differentiation (blue) in a publicly available 
dataset (Ross et al. 2007).  
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Figure 36. Enrichment of miR-449/34 associated genes with increasing airway 
wall thickness in patients with emphysema by GSEA. The set of genes that 
positively correlated with miR-449/34 family were enriched among genes that 
increase in expression with airway wall thickening of patients with emphysema 
(q≈0), both in (a) COPD and (b) ILD. Genes were ranked from those that 
increased in expression with thicker airway walls (red) to those that decreased in 
expression with thicker airway walls (blue) in an independent dataset of 60 
airway samples from 8 different patients with emphysema.  
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4.2.2 SNPs associated with disease that regulate miR-34/449 
Using the causality inference test (Millstein et al. 2009), we found 75 
SNPs in COPD and 60 SNPs in ILD that may regulate miR-449/34 family. Some 
of these SNPs have been previously associated with asthma, inflammation, 
cancer and other degenerative diseases by GRASP (Leslie, O’Donnell, and 
Johnson 2014). Top significantly associated SNPs with COPD or ILD by a 
Fisher’s exact test (q<0.25) are shown in Figure 37. 
To illustrate the association of the SNP data with miRNA and mRNA 
expression, an example is provided. We considered the following triplet obtained 
by the causality inference test: rs525770_C → miR-449a → CLUAP1. Figure 38 
shows the association of miR-449a with CLUAP1 expression (p<0.001). Figure 
39 illustrate the association of rs525770_C variant with miR-449a expression 
(p<1e-05) and CLUAP1 expression (p<0.002), respectively.  
Interestingly, using UCSC Genome Browser (Kent et al. 2002), we 
determined that rs525770_C falls in the genomic region of HS6ST3 gene. This 
gene is a Heparan sulfate (HS) sulfotransferase that modifies HS to generate 
structures required for interactions of HS with a variety of proteins. The protein 
coded by HS6ST3 is implicated in proliferation and differentiation, adhesion, 
migration, inflammation, blood coagulation, and other diverse processes. In 
addition, CLUAP1 (Clusterin associated protein 1) is known to be associated with 
immunoglobulin IgG1 (Gardin and White 2011). 
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Figure 37. SNPs that are significantly associated with COPD and ILD. (a) SNPs 
that are significantly associated with COPD by a Fisher’s exact test (q<0.25). (b) 
SNPs that are significantly associated with ILD by a Fisher’s exact test (q<0.25). 
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Figure 38. The association between miR-449a and CLUAP1 expression. 
 
 
Figure 39. The association of rs525770_C variant with (a) miR-449a expression 
and (b) CLUAP1 expression. 
  79 
4.2.3 Differential connectivity of miRNA-mRNA regulatory networks 
Next, we hypothesized that miRNA-mRNA regulatory networks are also 
differently connected between disease and normal states, independently of the 
associations with the SNP data. To test this hypothesis, a new approach to 
compute the module differential connectivity (MDC) of miRNA/mRNA association 
networks, is proposed. Each miRNA is assigned an MDC score, that captures the 
overall difference in the pairwise microRNA-gene correlation strengths between 
case and control networks (Figure 40). Then, we applied a permutation test by 
shuffling the class labels of the samples to determine the significance of real 
MDC scores. The computed p-values were adjusted by FDR correction. 
 
 
Figure 40. The differential connectivity of a miRNA is computed as the total 
squared difference between the edge weights of the two networks, scaled by the 
number of edges. 
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Using a 500-permutation test we identified 159 DC miRNAs in COPD and 
595 in ILD (FDR<0.1). Therefore, we found significant differences between case 
and control miRNA-mRNA regulatory networks in both COPD and ILD. Figure 41 
illustrates the significant difference between the real MDC score and the 
distribution of the random MDC scores obtained by 500 permutations, for miR-
30a-5p (FDR=0.002), the top DC miRNA in COPD. This miRNA has been 
previously associated with COPD (Steiling, Lenburg, and Spira 2009; Stephanie 
A Christenson et al. 2013).  
 
 
Figure 41. The permutation test assigns a p-value to each miRNA, by counting 
how many times the random MDC score is greater than the real MDC score. This 
example shows the real MDC score vs. the distribution of 500 random 
permutations for miR-30a-5p (FDR=0.002). 
 
Interestingly, members of miR-449/34 family were also found to be among 
the top ranked DC miRNAs (Table 7). 
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 miRNA DC FDR 
ILD 
miR-449c-5p 0.004 
miR-449b-5p 0.01 
miR-34c-5p 0.05 
miR-449a 0.07 
miR-34b-3p 0.09 
miR-34b-5p 0.1 
miR-34c-3p 0.13 
COPD 
miR-34c-5p 0.08 
miR-449c-5p 0.14 
miR-449b-5p 0.18 
miR-34b-3p 0.19 
Table 7. Differentially connected members of miR-449/34 family. 
 
In addition, the scale-free property of the disease-specific miRNA-mRNA 
regulatory networks was also evaluated. All three networks are scale-free (Figure 
42), however the correlation coefficient of the log-log plots increases when SNP 
data is incorporated as previously described in subsection 4.2.1 (Figure 29). 
 
Figure 42. The miRNA-mRNA regulatory networks follow a power law. The 
negative correlation between the frequency of node degree and the node degree 
indicates that the networks are scale-free. 
 
Control, r = -0.87 COPD, r = -0.86 ILD, r = -0.87
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4.3 Methods 
4.3.1 High-throughput sequencing of small RNA 
45 samples were prepared with Small RNA Sample Prep Kit v1.5 
(Illumina) and sequenced on the Genome Analyzer IIx (Illumina) according to the 
manufacturer’s protocol.  Multiplexed small RNA sequencing was conducted on 
the Illumina HiSeq 2000 for 319 lung tissue samples.  Briefly, one microgram of 
total RNA from each sample was used for library preparation with a TruSeq 
Small RNA Sample Prep Kit (Illumina).   
RNA adapters were ligated to 3’ and 5’ end of the RNA molecule and the 
adapter-ligated RNA was reverse transcribed into single-stranded cDNA. The 
RNA 3’ adapter was specifically designed to target miRNAs and other small 
RNAs that have a 3’ hydroxyl group resulting from enzymatic cleavage by Dicer 
or other RNA processing enzymes.   
The cDNA was then PCR amplified using a common primer and a primer 
containing one of 10 index sequences. The introduction of the six-base index tag 
at the PCR step allowed multiplexed sequencing of different samples in a single 
lane of a flowcell. Ten individual PCR-enriched cDNA libraries with unique 
indices in equal amount were pooled and gel purified together.  A 0.5% PhiX 
spike-in was also added in all lanes for quality control.   
Each library was hybridized to one lane of the 8-lane single-read flowcell 
on a cBot Cluster Generation System (Illumina) using TruSeq Single-Read 
Cluster Kit (Illumina).  The clustered flowcell was loaded onto HiSeq 2000 
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sequencer for a multiplexed sequencing run that consists of a standard 36-cycle 
sequencing read with the addition of a 7-cycle index read. 
4.3.2 miRNA alignment and quality control 
To estimate miRNA expression we used a small RNA sequencing pipeline 
previously described (Campbell et al. 2015). Similarly to the procedure described 
in 2.3.3, the 3′ adapter sequence was trimmed using the FASTX toolkit. Reads 
were aligned to hg19 using Bowtie v0.12.7 (Langmead et al. 2009).  
miRNA expression was quantified by the number of reads aligned to 
mature miRNA loci (miRBase v20) using Bedtools v2.9.0 (Griffiths-Jones 2004; 
Quinlan and Hall 2010).  
miRNA counts within each sample were RPM normalized, as previously 
described in section 2.3.3.  
The batch effects of the two sequencing protocols were removed by 
Combat (Johnson, Li, and Rabinovic 2007) and 13 outliers were removed by 
PCA; 351 patients were included in the downstream analysis. 
4.3.3 Quality control of the SNP data 
Using flashpca (Abraham et al. 2014) principal components of the SNP 
data were computed, for those patients with overlapping miRNA and mRNA data. 
As expected, race is clearly separated into two groups, corresponding to African-
American and Caucasian (Figure 43). This observation confirms that the SNP 
data is sound. 
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In addition, we can observe that the population structure may be a 
significant covariate of the eQTL analysis. However, this can be corrected by 
including the principal components into the model. 
 
Figure 43. PCA of the SNP data shows the separation of the African-American 
and Caucasian groups.  
 
4.3.4 eQTL analysis 
eQTLs (expression quantitative trait loci) are regions of the genome 
containing DNA sequence variants that cause expression changes of one or 
more transcripts. eQTL interactions can be either CIS or TRANS, based on the 
proximity between the SNP and the transcript (Figure 44).  
We utilized the subset of 262 lung tissue samples with miRNA expression 
profiled by sequencing, as well as publicly available Agilent gene expression 
array and Affymetrix SNP chip.  
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Genes and miRNAs associated with a SNP were identified by ANOVA 
(p<0.0005), while correcting for age, gender, smoking status, and population 
structure (the first three principal components). We considered both CIS and 
TRANS interactions, where CIS was defined as <1MB.  
 
Figure 44. This figure illustrates the molecular interaction of CIS and TRANS 
SNPs with an RNA transcript. In this example, the CIS SNP affects the promoter 
of gene A, while the TRANS SNP affects a transcription factor located upstream 
gene A. The figure was imported from (Wolen and Miles 2006), 
http://pubs.niaaa.nih.gov/publications/arcr343/306-317.htm  
 
4.3.5 Building causal disease specific networks using SNP, microRNA and 
mRNA data 
After we identified all genes and miRNAs associated with a SNP, as 
described in section 4.3.4,  we built integrative networks within the COPD, ILD, 
and control patients using the causality inference test (CIT) (Millstein et al. 2009). 
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This test is a previously established method for predicting SNP-miRNA-mRNA 
triplets where the SNP is regulating the expression of the miRNA and the miRNA 
is regulating the expression of the gene (Millstein et al. 2009).  
CIT assesses the hypothesis that a potential mediator between an initial 
randomized variable and an outcome variable is causal for that outcome. Causal 
and reactive models are defined as series of conditions of associations between 
the three variables, corresponding to SNP, microRNA and mRNA nodes. The 
significance of the test is computed for both the causal and reactive models. If 
the causal p-value is lower than 0.05 and the reactive higher than 0.05 then the 
call is considered causal. If both p-values are greater than 0.05 then the call is 
independent, and if both p-values are lower than 0.05, then the causality cannot 
be inferred.  
We selected those SNP-miRNA-mRNA triplets where the SNP-mRNA 
relationship is defined by a miRNA mediator, filtering out independent 
relationships and those triplets where the SNP is not associated with the miRNA. 
The number of connections at each step of the network construction are shown 
in Figure 45. 
Next, we compared the disease networks with the control network and 
evaluated those miRNAs that were differentially connected with their targets 
between the two states. For each microRNA in a CIT triplet, we counted how 
many genes were connected in each state. To assign significance, we applied a 
Fishers’s exact test the ratio of connected genes between disease and control. 
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Figure 45. Number of significant interactions at each step of network construction 
in COPD, ILD and control groups. 
 
4.3.6 Validation of the gene modules by gene enrichment 
Using two independent datasets, we validated the miR-449/34 gene 
module by gene enrichment using GSVA (Hänzelmann, Castelo, and Guinney 
2013) and GSEA (Subramanian et al. 2005).  
First we performed gene enrichment of the gene module in a publically 
available dataset that provides gene expression measurements over time when 
airway basal cells are differentiated at an air-liquid interface (ALI) (Ross et al. 
2007). First, the time points were correlated with the GSVA scores of the gene 
set corresponding to miR-449/34 gene module. The results were confirmed by 
  88 
GSEA, where genes were ranked from those that increased in expression with 
time of differentiation to those that decreased in expression with time of 
differentiation in the ALI data, using a linear mixed-effects model (lme() R 
function). 
The second validation dataset was generated by our laboratory, providing 
60 airway gene expression samples profiled from 8 patients with emphysema 
(Campbell et al. 2012). We performed a GSVA analysis by correlating the airway 
wall thickness measure with the GSVA scores of the gene set that corresponds 
to the miR-449/34 gene module. These results were also confirmed by GSEA, 
where the genes were ranked from those that increased in expression with 
thicker airway walls to those that decreased in expression with thicker airway 
walls, using a linear mixed-effects model (lme() R function). 
 
4.4 Discussion 
 This work presents novel insights about the complex mechanisms of lung 
pathogenesis. Using the causality inference test, we identified potential miRNA 
drivers of COPD and ILD. We show that there exists a significant number of 
different miRNA-mRNA interactions between disease and normal states. In 
addition, the networks obtained by this methodology are biologically meaningful, 
with a significant scale-free profile.  
Among the top differentially connected miRNAs in COPD and ILD we 
found miR-449/34 family. Members of this family have been previously 
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associated with inflammatory lung diseases. Previous studies have shown that 
miR-449/34 family regulates mucociliary differentiation by directly targeting the 
NOTCH pathway (Marcet et al. 2011; Lizé, Klimke, and Dobbelstein 2011; Bae et 
al. 2012; Liu et al. 2015; Chevalier et al. 2015). In addition, we validated the 
association of these miRNAs with gene modules implicated in the airway 
epithelial cell differentiation. Besides miR449/34 family, we also found miR-4423 
to be differentially connected in COPD. Expression of this miRNA has been 
previously associated with airway differentiation in smokers with lung cancer 
(Perdomo et al. 2013).  
We generated a novel small-RNA sequencing dataset and highlighted the 
most dysregulated miRNAs in COPD and ILD by an integrative network 
approach. This work is a step forward in understanding the complex mechanisms 
of lung pathogenesis and developing new therapeutic strategies. 
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CHAPTER FIVE 
Conclusions and future directions 
 
This work provides new data and methods for biomarker discovery. We 
demonstrate for the first time the presence of a microRNA expression field in the 
bronchial epithelium of patients with lung cancer. While microRNA expression 
changes have already been associated with human cancers, we show for the first 
time that these alterations are measurable from bronchial epithelial tissue. 
A bronchial biomarker for lung cancer detection has been developed by 
integrating microRNA and mRNA expression. By incorporating microRNA data, 
the proposed biomarker improves the performance of an existing bronchial 
mRNA predictor in an independent test set. This study is a proof of concept 
showing that bronchial microRNAs can be used to predict the presence of lung 
cancer. Building upon an existing clinical test, this work has important clinical 
implications. In future work we propose to profile nasal microRNAs and integrate 
them with nasal mRNAs to develop a robust and less invasive biomarker for lung 
cancer detection.  
In addition, miR-146a has been characterized in many cancer tissues and 
its role as a tumor suppressor has been previously established (Labbaye and 
Testa 2012). Knockdown experiments in human breast cancer cells have shown 
that BRCA1/EGFR interaction is regulated by miR-146a, miR-146a expression 
being positively correlated with the expression of BRCA1 tumor suppressor. We 
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plan to further investigate the role of this miRNA in bronchial tissue and lung 
cancer development.  
The second part of this work proposes a new graphical tool for binary 
classification problems, with application in biomarker discovery. Clinical data is 
limited, and most of the times the number of samples is much smaller than the 
number of molecular features, making it difficult to train different prediction 
algorithms. The results of different classifiers may differ based on the number of 
samples, the number of features or the class prevalence of a dataset. The goal of 
this software tool is to standardize the biomarker discovery process, when 
multiple algorithms are tested in cross-validation on the same dataset.  
A web-based user-interface has been developed to facilitate the biomarker 
selection process and sort through a thousand potential biomarkers. This 
interface is user-friendly and guides the user through the entire process of 
biomarker selection and interpretation. This software may serve as a useful 
resource for the translational bioinformatics research community. Future work 
includes incorporating the biomarker pipeline and the GUI into a more accessible 
web-based system that can run on a cloud computing platform. In addition, other 
methods will be added to the existing collection of algorithms. Ensemble methods 
will be tested and compared with individual methods. 
Finally, COPD and ILD disease-specific networks were analyzed. 
Interestingly, both the microRNA-mRNA regulatory networks and those that 
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incorporate genetic data (SNP) with microRNA and mRNA expression were 
significantly differentially connected between disease and normal states.  
Using a causality inference test to infer SNP-microRNA-mRNA causal 
relationships, potential drivers of COPD and ILD, such as miR-449/34 family, 
were identified. These interesting molecular associations will further be 
investigated and validated by in-vitro experiments. This study is a step forward 
understanding the complex molecular mechanisms underlying chronic 
inflammatory lung diseases. 
This thesis addresses three major health problems, such as lung cancer, 
COPD and ILD. In addition, it proposes new integrative approaches for biomarker 
discovery and provides new insights into the complex molecular mechanisms 
underlying smoking related lung diseases. 
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